Company Overview and News


Add DSKYF
to your dashboard

Headline News

Exelixis: Primed For Excellence

2017-11-17 seekingalpha
For investors a bit late to the game, it appears now is a good time to initiate a position in Exelixis. (109-0)

Singh brothers restructure Fortis, Religare as they wrestle with debt

2017-11-15 livemint
Mumbai: Two companies controlled by tycoons Malvinder and Shivinder Singh announced a reorganization as the brothers wrestle with debt and legal tangles. (2-0)

Singh Brothers' Firms Reorganize as Tycoons Wrestle With Debt - Bloomberg

2017-11-15 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (2-0)

Biotech Stock Roundup: Dynavax Vaccine Gets FDA Nod, Loxo Inks Deal with Bayer

2017-11-15 zacks
With just a handful of biotech companies left to report third quarter results, focus is back on regulatory and pipeline updates. Among major news this week, Dynavax Technologies (DVAX - Free Report) finally gained FDA approval for its hepatitis B vaccine while Loxo Oncology (LOXO - Free Report) was in the news for its collaboration agreement with Bayer. Recap of the Week’s Most Important Stories Loxo down despite Bayer Deal worth Up To $1. (226-0)

Ligand Pharmaceuticals' (LGND) Presents at Analyst Day (Transcript)

2017-11-15 seekingalpha
Welcome. Thank you, everyone, for joining us. Ligand's end-of-the-year Analyst Day 2018 and beyond. We appreciate the turnout. We got a nice group on the audience today. The attendees on the webcast that continue to add and we really do appreciate your attention here at the end of day and close to the end of the year. My name is John Higgins, I'm the CEO of Ligand. I'm joined by several of our colleagues. (115-0)

Daiichi Sankyo Co., Ltd. ADR 2018 Q2 - Results - Earnings Call Slides

2017-11-12 seekingalpha
The following slide deck was published by Daiichi Sankyo Co., Ltd. ADR in conjunction with their 2018 Q2 earnings call. (2-1)

ArQule's (ARQL) CEO Paolo Pucci on Q3 2017 Results - Earnings Call Transcript

2017-11-09 seekingalpha
Good day, ladies and gentlemen and welcome to the ArQule Third Quarter 2017 Earnings Conference Call. At this time all participants are in a listen-only mode. Later there will be a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder this conference call is being recorded. (11-1)

Portola Pharmaceuticals' (PTLA) CEO William Lis on Q3 2017 Results - Earnings Call Transcript

2017-11-07 seekingalpha
Welcome to Portola Pharmaceuticals Conference Call. This call is being recorded. At the end of the Company’s prepared remarks, we will open the call for questions and we'll provide specific instructions. (137-0)

Inovalon's (INOV) CEO Dr. Keith Dunleavy on Q3 2017 Results - Earnings Call Transcript

2017-11-04 seekingalpha
Good day, ladies and gentlemen, and welcome to the Inovalon Third Quarter 2017 Earnings Call [Operator Instructions]. As a reminder, this conference is being recorded. (2-0)

News Live: SC refuses to extend relief on deposit of demonetised notes

2017-11-03 moneycontrol
The Supreme Court has disposed of 14 individual petitions seeking nod to deposit demonetised currency and asks petitioners to file plea before the Constitution bench, reports PTI. Besides examining the Centre's decision on demonetisation, the Constitution bench would also deal with individual pleas seeking to deposit demonetised notes. Meanwhile, the government has said it will not prosecute those holding old currency notes for now. (22-1)

News Live: Torrent Pharma set to buy Unichem Labs’ local ops for Rs 3,500cr today

2017-11-03 moneycontrol
Torrent Pharmaceuticals is set to acquire the domestic formulations business of Unichem Laboratories in a deal estimated at about Rs 3,500 crore, reports The Times of India. A formal announcement on the slump sale of Unichem's division to Torrent is expected in the next few days, or as early as on Friday, sources said. The deal-making would help the Sudhir Mehta-spearheaded Torrent to strengthen its footprint in the domestic market, especially in the cardiac, neuro and gastro-intestinal segments where Unichem has a significant presence. (17-0)

Paper: GMI-1271 Improves Efficacy and Safety of Chemotherapy in R/R and Newly Diagnosed Older Patients with AML: Results of a Phase 1/2 Study

2017-11-01 ash.confex
Daniel J. DeAngelo, MD, PhD1, Brian A Jonas, MD, PhD2, Jane L. Liesveld, MD3, Dale L. Bixby4*, Anjali S. Advani, MD5, Paula Marlton, MBBS6, Michael O'Dwyer, MD7, John L Magnani, PhD8, Helen M. Thackray, MD8 and Pamela S. Becker, MD, PhD9 (45-0)

Daiichi Sankyo Co., Ltd. ADR 2017 Q2 - Results - Earnings Call Slides

2017-10-31 seekingalpha
The following slide deck was published by Daiichi Sankyo Co., Ltd. ADR in conjunction with their 2017 Q2 earnings call. (2-0)

BRIEF-Daiichi Sankyo announces enliven Phase 3 study of Pexidartinib met primary endpoint in Tenosynovial giant cell tumor​

2017-10-31 reuters
* ‍Daiichi Sankyo announces enliven Phase 3 study of Pexidartinib met primary endpoint in Tenosynovial giant cell tumor​ Source text for Eikon: Further company coverage: (2-0)

Bristol-Myers (BMY) Misses on Q3 Earnings, Opdivo in Focus

2017-10-26 zacks
Bristol-Myers Squibb Company’s (BMY - Free Report) third-quarter 2017 earnings of 75 cents per share fell short of the Zacks Consensus Estimate as well as the year-ago quarter earnings of 77 cents. (258-0)